Annual Financial Statements 31 December 2025
30 April, 2026
Genflow Biosciences Enters Strategic Technology Collaboration with Acuitas Therapeutics
20 April, 2026
International Patent Publication Expands Protection for SIRT6-Based Muscular Disease Program
13 April, 2026
Genflow Voting Rights
31 March, 2026
Receipt of First Tranche of €4 Million Non-Dilutive Funding from Wallonia Region for GF-1002 Development
02 March, 2026
Positive Preliminary Interim Results from SLAB Clinical Trial of SIRT6 Gene Therapy in Aged Dogs
12 February, 2026
GM Notice February 2026
11 February, 2026
GM Proxy February 2026
11 February, 2026